Fi­bro­Gen re­ports third PhI­II fail­ure in two months, this time in id­io­path­ic pul­monary fi­bro­sis

Fi­bro­Gen’s pam­revlum­ab failed an­oth­er Phase III study — the biotech’s third late-stage miss in two months — and its shares plum­met­ed 76% be­fore Mon­day’s open­ing bell.

The com­pa­ny said Mon­day that its an­ti­body pam­revlum­ab was not bet­ter than place­bo at a lung func­tion test ex­am­in­ing the amount of air peo­ple can ex­hale in a 356-per­son ran­dom­ized tri­al called ZEPHYRUS-1. The p-val­ue was 0.29 on the pri­ma­ry end­point, mea­sur­ing a change from base­line in forced vi­tal ca­pac­i­ty at week 48. It al­so wasn’t bet­ter at de­lay­ing dis­ease pro­gres­sion in the first of two Phase III tri­als to read out for peo­ple with id­io­path­ic pul­monary fi­bro­sis. Fi­bro­Gen said it was “gen­er­al­ly safe and well tol­er­at­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER